Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls

References

• Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat.52, 65–77 (1998).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist11, 318–324 (2006).
   PubMed Web of Science ®Google Scholar
• Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist13, 1114–1119 (2008).
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol.20, 719–726 (2002).
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol.23, 2162–2171 (2005).
   PubMed Web of Science ®Google Scholar
• Pegram MD, Konecny GE, O’Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst.96, 739–749 (2004).
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23, 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol.23, 2502–2512 (2005).
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res.66, 1630–1639 (2006).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Esteva FJ. Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest.24, 187–191 (2006).
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell6, 117–127 (2004).
   PubMed Web of Science ®Google Scholar
• Nahta R, Takahashi T, Ueno NT et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res.64, 3981–3986 (2004).
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res.8, 215 (2006).
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res.65, 11118–11128 (2005).
   PubMed Web of Science ®Google Scholar
• Lu CH, Wyszomierski SL, Tseng LM et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res.13, 5883–5888 (2007).
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst.99, 628–638 (2007).
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Razis E, Tsavdaridis D et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin. Breast Cancer4, 120–125 (2003).
   PubMedGoogle Scholar
• Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin. Breast Cancer5, 52–58 (2004).
   PubMedGoogle Scholar
• Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol.22, 1063–1070 (2004).
   PubMed Web of Science ®Google Scholar
• Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer6, 63 (2006).
   PubMed Web of Science ®Google Scholar
• Fabi A, Metro G, Ferretti G et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast17, 499–505 (2008).
   PubMed Web of Science ®Google Scholar
• Cancello G, Montagna E, D’Agostino D et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res.10, R60 (2008).
   PubMed Web of Science ®Google Scholar
• Montemurro F, Redana S, Nole F et al. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer8, 209 (2008).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J. Clin. Oncol.27(12), 1999–2006 (2009).
   PubMed Web of Science ®Google Scholar
• Extra J-M, Antoine E-C, Vincent-Salomon A et al. Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res. Treat.100(Suppl. 1), S102 (2006).
   Google Scholar
• Nahta R, Esteva FJ. In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells. Cancer Chemother. Pharmacol.53, 186–190 (2004).
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med.355, 2733–2743 (2006).
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein H, Pegram M et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J. Clin. Oncol.23(Suppl. 16), (2005) (Abstract 3004).
   Google Scholar
• Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol.26, 1993–1999 (2008).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol.26, 1015 (2008).
   Google Scholar